This study aimed to analyze the impact factors and outcome of antithrombotic therapy in elderly patients over 65 years old that suffered from atrial fibrillation (AF). A total of 256 elderly patients with AF over 65 years old were divided into 3 groups: 65-74 years old (N = 86), 75-84 years old (N = 122), and over 85 years old (N = 48). The clinical characteristics, antithrombotic therapy, and its related impact factors were retrospectively analyzed. Of all patients, 187 received antithrombotic therapy. In the 65-74 yearold group, 78 patients received antiplatelet treatment (90.7%) and 5 patients received anticoagulation treatment (5.8%). In the 75-84 year-old group, 76 patients received antiplatelet treatment (62
INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia observed in clinical practice (Crandall et al., 2009 ). The incidence of AF increases with age, and for elderly patients aged over 80 years, it can reach up to 10% (Go et al., 2001; Freestone and Lip, 2003) . Ischemic stroke and other thromboembolic events are the major AF-related complications (Spence, 2009) . Thromboembolic events could occur at least once in 35% of patients with AF. Moreover, recurrent stroke in patients who had a stroke or transient ischemic events are widely common, with the incidence reaching up to 12%. Old age is not only a risk factor for developing AF, but is also an independent risk factor for thromboembolic events, including ischemic stroke (Lin et al., 1996; Marini et al., 2005; Böhm et al., 2009) . Therefore, elderly patients can benefit more from antithrombotic therapy. In recent years, the management of thrombosis prevention in AF patients has shown continuous development. The European Society of Cardiology (ESC) published related guidelines in 2010 (hereafter referred to as the ESC2010 guidelines) (Camm et al., 2010) . Subsequently, the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA)/Heart Rhythm Society (HRS) updated their guidelines (hereafter referred to as ACCF/AHA/HRS 2011 guidelines) (Fuster et al., 2011; Wann et al., 2011a,b) , and improved anticoagulant treatment of AF. Based on CHA2DS2-VSAc scoring, the ESC guidelines for the stratification of stroke risk in patients with AF in 2010 stated that effective anticoagulation treatment was recommended for almost all elderly patients with AF. However, because of complex pathophysiological changes in elderly patients, there are still gaps between the ESC guide and antithrombotic therapy for AF in China. This study aimed to evaluate the current state of antithrombotic therapy in elderly patients with AF in everyday clinical practice in China, analyze the factors influencing the treatment, and provide clinical advice for the standardization of antithrombotic therapy for elderly patients.
MATERIAL AND METHODS

Subjects
A total of 256 elderly patients over 65 years old with AF admitted to our hospital in the past 3 years were recruited for the study, including 249 males and 7 females. The average age of all patients was 80.6 ± 7.2 years (range: 65-98 years). The primary diseases of the patients were as follows: 229 patients had coronary atherosclerotic heart disease, 225 patients had hypertensive heart disease, 7 patients had dilated cardiomyopathy, 54 patients had pulmonary heart disease, and 3 patients had hyperthyroid heart disease. This study was conducted in accordance with the declaration of Helsinki and with approval from the Ethics Committee of the Chinese PLA General Hospital. Written informed consent was obtained from all participants.
According to the suggestions of the working group of arrhythmia of the European Society for Cardiovascular Disease (WGA-ESC) and the North American Society of Pacing and Electrophysiology (NASPE), the classification of AF was as follows: 1) in paroxysmal AF, the mean duration of AF is less than 7 days, and generally <48 h, and is mostly selflimiting; 2) in persistent AF, the duration of AF is more than 7 days, or less than 7 days but patients need drugs or electrical cardioversion; 3) in permanent AF, AF cardioversion fails or cardioversion is no longer attempted (Lévy et al., 2003) . The AF of the 256 patients was confirmed by electrocardiogram, of which 156 cases had paroxysmal AF, 64 cases had persistent AF, and 36 cases had permanent AF. The AF course ranges from 8 months to 36 years, and the average course is 15.8 ± 6.2 years. Accessory examinations were conducted to determine whether the left atrial diameter was 38 ± 3 mm under cardiac ultrasonography.
Grouping
All patients were divided into three groups by age: the 65-74 year-old group (86 cases), the 75-84 year-old group (122 cases), and the over 85 year-old group (48 cases).
Treatment
A total of 243 patients received drug therapy, including Metoprolol, Cordarone, and Propafenone, to control the ventricular rate. Aspirin and clopidogrel were used for antiplatelet therapy, and warfarin was used as anticoagulation therapy. Thirteen patients received pacemaker (VVI, Medtronic) treatment. The indications for VVI pacemaker therapy were persistent AF with a slow ventricular rate and an atrioventricular conduction blockage.
Statistical analysis
All parameters are reported as means ± standard deviation. The discrete variables are expressed as percentages. The SPSS18.0 statistical software was adopted for data analysis, and comparisons between groups were conducted using the chi-squared test. P < 0.05 indicated that differences were considered to be statistically significant.
RESULTS
Antithrombotic therapy
Of all patients, 210 received antithrombotic treatment (82.0%) and 46 (18.0%) did not. Antithrombotic aspirin was used in 75 patients, clopidogrel was used in 78 patients, 34 patients were treated with both aspirin and clopidogrel, and 23 patients received warfarin. In patients aged 65-74 years old, 90.7% of patients received antiplatelet therapy, and 5.8% received anticoagulant therapy. In patients aged 75-84 years, 62.3% of patients received antiplatelet therapy and 11.5% received anticoagulant therapy. In patients over 85 years old, 68.8% of patients received antiplatelet therapy and 8.3% received anticoagulation therapy. The use of antithrombotic therapy with respect to the different age groups is shown in Table 1 .
Antithrombotic therapy in atrial fibrillation
Comorbidities in elderly patients
Fifty patients had tumors (20.3%), 9 cases of which were seen in the 65-74 year-old group, 28 were in the 75-84 year-old group, and 13 were in the over 85 year-old group. The tumors were observed in several different systems, including meningiomas, nasopharyngeal squamous cell carcinoma, parathyroid adenoma, lung cancer, stromal tumor in the stomach, gastric cancer, cardia carcinoma, hepatocellular carcinoma, carcinoma of the sigmoid colon, renal clear cell carcinoma, renal papillary carcinoma, bladder cancer, prostate cancer, and chronic lymphocytic leukemia ( Of all patients, 42 had prior bleeding or diseases of bleeding tendency before antithrombotic treatment, including brain hemorrhage, hemorrhagic gastritis, duodenal bulb ulcer, renal anemia, thrombocytopenia, and so on. Fifty-two patients had thrombosis or embolism disease tendencies before antithrombotic therapy, including atrial thrombosis, deep venous thrombosis, insufficient blood supply of vertebral basilar artery, cerebral lacunar infarction, peripheral vascular embolization, and so on. Twenty-three of these patients had two kinds of the diseases mentioned above.
Effects of antithrombotic therapy
Eleven patients had atrial thrombosis and deep vein thrombosis during antiplatelet therapy (5.9%); 1 patient was 65-74 years old, 7 patients were 75-84 years old, and 3 patients were over 85 years old. There was no new onset atrial thrombosis or deep vein thrombosis events in patients who received anticoagulant therapy ( 
Safety of antithrombotic therapy
Five patients had gastrointestinal hemorrhages during antiplatelet therapy (2.7%). Two patients had gastrointestinal hemorrhage and 3 patients had brain hemorrhages during anticoagulant therapy (21.7%).
DISCUSSION
AF is often accompanied by many diseases in elderly patients. In this study, we observed that most elderly patients with AF had comorbidities such as coronary heart disease, hypertension, and diabetes. We ranked the risk of stroke related to AF according to the CHADS2 score. Patients with a low risk of a thromboembolic event may benefit from aspirin treatment. The combination of aspirin and clopidogrel or warfarin should be considered for patients with intermediate and high risks (Gage et al., 2001; Singer et al., 2008) . Most of the elderly patients with AF have an intermediate or high risk of stroke, and therefore the combination of antiplatelet or anticoagulant therapy should be given. The NASPEAF random test confirmed that the incidence of AF was significantly higher in patients older than 75 years compared to that of younger patients, and combined antiplatelet and anticoagulation therapy could significantly reduce the incidence of vascular events (Pérez-Gómez et al., 2007) . Lip et al. (2010) evaluated 1084 patients with AF based on the European Heart Survey with the CHA2DS2-VSAc score, confirming that the stroke incidence increased year by year as the integral age increased. Therefore, based on the CHADS2 scoring program, the new integration program filtered actual "low risk" patients while scaling down the proportion of patients with "medium risk", so that more than 90% of patients belonged to "high risk" groups. According to CHA2DS2-VSAc scoring, the ESC guidelines for the stratification of stroke risk in patients with AF in 2010, and recommendations that directly select antithrombotic therapy based on risk factors, almost all elderly patients with AF were treated with anticoagulation. The present study showed that most of the elderly patients with AF were treated with a single drug for antiplatelet therapy, and clopidogrel was most commonly used. Antiplatelet therapy was more efficient in the "younger" elderly group (65-74 year-olds) than in the older age group (over 75), which may have been due to the higher incidence of tumors, hemorrhages, and ischemia tendency diseases in the "older" elderly patients with AF. Ischemia-tendency diseases were another problem that clinicians had to face for antiplatelet therapy. Embolism occurred in 5.9% of the patients who had not achieved a sufficient protective effect from antiplatelet treatment. Only 8.9% of the patients were treated with warfarin for anticoagulation, and although embolic ischemia did not occur, bleeding occurred in 21.7% of these patients. In addition, the effect of antiplatelet therapy was not as satisfactory as that of anticoagulation therapy in elderly patients with AF. At the same time, these observations indicated that anticoagulant therapy was not adequate in elderly patients with AF; its safety was not fully monitored and the risk of bleeding was not fully confirmed. CHA2DS2-VSAc scoring is based on the European Heart Survey, and it is unknown whether any of these patients were from an Asian population. Therefore, whether CHA2DS2-VSAc scoring is suitable for the clinical diagnosis and treatment of AF in China needs further evaluation using a large Chinese AF cohort.
This study showed that there were comorbidities in elderly patients with AF, such as blood diseases (iron deficiency anemia, thrombocytopenia), renal insufficiency, and anemia due to kidney disease. Many factors could lead to the suboptimal thromboprophylaxis observed in this cohort. In addition, a high occurrence of tumors appeared in the elderly patients. Approximately one third of the patients in the over 85 year-old group had tumors in different systems, which affected the function of the blood coagulation system. Furthermore, senile dementia and high risk of falling could increase the difficulty of antithrombotic therapy (Jacobs et al., 2009 ). In addition, diseases of bleeding or thrombosis appeared in the course of therapy in approximately 50% of the older patients, and they coexisted in some cases. The factors affecting bleeding and thrombosis were reciprocally interwoven, leading to contradictions of antithrombotic therapy in patients with AF, especially in the elderly. This resulted in contradictions of sufficient antithrombotic treatment, gastrointestinal and brain bleeding, insufficient antithrombosis, and deep vein and atrial thrombosis. However, it was found that patients with a high risk of hemorrhage could obtain a greater benefit from antithrombotic therapy (RobertEbadi et al., 2009) . Therefore, elderly patients with AF should carefully assess the risk-benefit ratio of antithrombotic therapy in selecting appropriate treatment strategies.
In conclusion, this data showed several features of elderly patients with AF: 1) various pathophysiologies were observed, including high rates of cancer, which affected blood coagulation, suggesting that the risk-benefit ratio of various treatments needs to be measured to improve the patients' quality of life and extend their lifespans as far as possible; 2) complex pathophysiological statuses were observed in elderly patients with AF, which caused excessive contraindications and relative contraindications, thus limiting the benefits of antithrombotic therapy; 3) there were high risks of thrombosis and bleeding in elderly patients, which conflicted with the antithrombotic therapy. The conflict manifested as a higher risk of thrombosis and bleeding complications during treatment, which increased the difficulty to choose antithrombotic therapy and the risk of bleeding in antithrombotic therapy.
Previous risk assessments on hemorrhage during anticoagulation therapy in patients with AF have yielded vague results. The ESC2010 guidelines quantified the bleeding risk assessment by using HAS-BLED programs to evaluate the risk of bleeding in AF patients with anticoagulation therapy. Under these guidelines, a bleeding score of more than 3 points prompted the "high risk" classification, and such "high risk" patients should be cautious when receiving warfarin or aspirin therapy. Two clinical trials, SPORTIF III and SPORTIF IV, showed that the HAS-BLED score could effectively predict the risk of bleeding in patients with AF (Lip et al., 2011) . However, whether HAS-BLED programs are suitable for elderly patients with AF in China still needs further confirmation based on clinical evidencebased medicine, especially with respect to the risk stratification of bleeding in senile patients with AF to benefit patients who would receive antithrombotic therapy. Indeed, suboptimal thromboprophylaxis is commonly widely applied in clinical practice, especially in East Asian countries. The rate of oral anticoagulant (OAC) use is 0.5-28% in China, Singapore, Malaysia, and Taiwan (Guo et al., 2013) . A recent Chinese quality evaluation of stroke care and treatment registry demonstrated that OAC was used in only 20% of 499 stroke patients with AF (Gao et al., 2013) . There are several possible reasons to explain these results. The main reason can be attributed to limitations of warfarin. This drug needs routine monitoring and dose adjustments, and the target internal normalized ratio (INR) range is narrow, which is likely to be influenced by broad interactions with food and other drugs. Secondly, our patients were elderly individuals who were already at risk for thrombotic and bleeding events considering their comorbidities, leading to INR instability and difficulties in regulating INR. Thirdly, the risk for bleeding in response to warfarin in Asian populations may be related to differences in the prevalence of certain polymorphisms of genes that influence warfarin pharmacokinetics and pharmacodynamics (Medi et al., 2010) . The development of novel oral anticoagulants will provide a valuable therapeutic option in Asian patients with AF who are at risk for stroke.
Only 23 patients were treated with anticoagulation therapy of the elderly patients with AF, leading to a relatively small sample size, which limits the comparison of anticoagulation therapy across different age groups. Therefore, expanding the sample size in a similar study is needed to further confirm whether the 2010 ESC AF guidelines and American ACCF 2011 guidelines can be suitably applied for antithrombotic therapy of "younger" and "older" elderly patients with AF therapy in China.
